Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it? - Wikidata - awgldk - TriplyDB

Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it?

Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it?

http://www.wikidata.org/entity/Q43825515

about

Neuroprotection in Parkinson's disease: love story or mission impossible?

P2860

Q43265626-2C0A4902-7056-4A3C-ADCC-44084D4F2687

P2860

Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it?

http://www.wikidata.org/entity/Q43825515

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it?

@en

Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it?

@nl

type

label

Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it?

@en

Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it?

@nl

prefLabel

Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it?

@en

Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it?

@nl

P1433

Q43825515-67733C02-D763-49DC-A15E-CBB083FD55ED

P1476

Q43825515-BCD50265-705A-484E-94D8-EE224B5DC431

P2093

Q43825515-B535D9D9-0AD1-4191-A62A-C4915CEF092C

P2860

Q43825515-00EF6DEF-1B79-4933-BA46-1DD2A56C0EA9

Q43825515-0C06BD95-B5B5-4FC4-B059-0BF7F3D02EE4

Q43825515-3ADE53EF-4571-4F36-9B9B-04C409219F1A

Q43825515-4808E99E-83C5-4C62-A09F-E1BF94669DC0

Q43825515-7D2B9D11-9C2D-48A0-883A-EAE841705C3C

Q43825515-C762EDDC-AE73-459C-9012-4D25FB2CC348

Q43825515-E34670EE-94CF-4DA4-A2EB-3CCA5621E80D

Q43825515-E7BD00B2-1058-4449-B7A0-607D246DA4E2

P304

Q43825515-82CDE53E-AAF8-445C-8385-53CEBE46873A

P31

Q43825515-C2468069-00E3-4BED-AEFE-389D2B26536A

Q43825515-aa7797d7-740b-4180-81d3-736d240d2e20

P356

Q43825515-350148AD-C5DD-4DEB-BB31-5E26C67B5200

P407

Q43825515-2A2B4A95-6E20-46B8-B855-9A7A7D1DAB74

P433

Q43825515-4370DC92-DFA2-49E7-B35C-F719B875063F

P478

Q43825515-E453726B-8133-4078-884F-FB0494657BD9

P50

Q43825515-B3B7FB03-2FE9-4A76-A6F0-B85080F72834

P577

Q43825515-2456720D-56A7-4888-B5C0-9415DD85ACCF

P698

Q43825515-EB5486FA-CF30-44D0-B583-E5953434104A

P921

Q43825515-B57C9628-336B-4F92-8EA9-59C8A054B3E1

P356

P1433

Movement Disorders

P1476

Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it?

@en

P2093

Stoessl AJ

http://www.w3.org/2001/XMLSchema#string

P2860

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations

Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.

[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels.

Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices.

Nigrostriatal function in humans studied with positron emission tomography.

Novel observations with FDOPA-PET imaging after early nigrostriatal damage.

[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.

P304

804-806

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.1192

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2001-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11746608

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease